Remedy Entertainment FY2026 H1 Business Review

Remedy Entertainment Plc

August 11 , 202 6
Half -Year Financial Re port
JANUARY – JUNE 202 6

REMEDY ENTERTAINMENT PLC. LUOMANPORTTI 3, 02200 ESPOO, FINLAND 2 (22 )

Remedy Entertainment Plc | Stock exchange release | August 11 , 202 6, at 09:00 a.m.
EE ST

Remedy Entertainment Plc | Half -Year Financial Re port January –June 202 6

CONTROL Resonant set to launch on September 24 th
Marketing ramp ed up while revenue decreased

The Half -Year Financial Re port is unaudited. Figures in parentheses refer to the
comparison period in the previous year, unless otherwise stated .

Highlights from April –June 202 6
• Revenue de creased by 40 .0% to EUR 1 0.2 (16.9) million.
• EBITDA was EUR -2.4 (4.2) million.
• Operating profit (EBIT) was EUR -3.9 (-0.5) million, and the operating profit margin
was -38 .8% ( -2.7%) of revenue.
• Cash flow from operations was EUR -0.7 (3.1) million .
• In June 202 6, Remedy announced that CONTROL Resonant will launch worldwide
on September 24, 2026 .

Highlights from January –June 2026
• Revenue decreased by 23 .1% to EUR 23 .3 (30 .3) million.
• EBITDA was EUR 0.5 (6.8) million.
• Operating profit (EBIT) was EUR -2.9 (0.8) million, and the operating profit margin
was -12 .5% ( 2.8%) of revenue.
• Cash flow from operations was EUR 7.6 (-3.5) million.
• In February 2026, Jean -Charles Gaudechon was appointed as the CEO of Remedy
as of March 1, 2026.

REMEDY ENTERTAINMENT PLC. LUOMANPORTTI 3, 02200 ESPOO, FINLAND 3 (22 )

Key Figures
MEUR, IFRS, Group, unaudited 4–6/2026 4–6/2025 1–6/202 6 1–6/2025 1–12/2025
Revenue 10.2 16.9 23.3 30.3 59.5
Change in revenue, % -40 .0% 63 .5% -23.1% 43.4% 17.5%
EBITDA -2.4 4.2 0.5 6.8 11.3
EBITDA, % of revenue -23.6% 24 .9% 2.3% 22 .4% 19.1%
Operating profit (EBIT) -3.9 -0.5 -2.9 0.8 -14.9
Operating profit, % of revenue -38 .8% -2.7% -12 .5% 2.8% -25.0%
Result for review period -3.2 -0.6 -2.8 0.0 -13.0
Result for review period, % of
revenue -31 .9% -3.4% -11.9% 0.1% -21.9%
Balance sheet total 85.1 97. 5 85.1 97. 5 87.5
Cash flow from operations -0.7 3.1 7.6 -3.5 4.5
Net cash 11.8 10.0 11.8 10.0 11.1
Cash and liquid investments 29 .6 27.6 29.6 27.6 29.4
Net gearing, % -21.4% -14.4% -21 .4% -14.4% -19.7%
Equity ratio, % 65.3% 72.8% 65.3% 72.8% 67.4%
Capital expenditures 3.8 5.5 7.1 9.2 14.3
Average number of personnel
during review period (FTE) 37 2 370 373 36 6 371
Headcount at the end of period 379 385 379 385 387
Earnings per share, € -0.24 -0.04 -0.20 0.0 0 -0.96
Earnings per share, € (diluted) -0.24 -0.04 -0.20 0.0 0 -0.96
Number of shares at the end of
period 13,640,451* 13, 640 ,451 13, 640 ,451* 13, 640 ,451 13,640,451*
*Includes 50,000 treasury shares.

REMEDY ENTERTAINMENT PLC. LUOMANPORTTI 3, 02200 ESPOO, FINLAND 4 (22 )

Comments by CEO Jean -Charles Gaudechon
Remedy’s second quarter was defined by our announcement of the launch date for
CONTROL Resonant . Marketing for CONTROL Resonant ramped up during the
second quarter, reducing the profitability of the reporting period , as anticipated .

Revenue was EUR 1 0.2 (16 .9) million, decreasing 40 .0% from the comparison period.
Revenue from game sales and royalties was EUR 3.8 (9.5) million . The comparison
period included revenue related to the launch of FBC: Firebreak , including initial
accruals from subscription service agreements . Development fees , originating from
Max Payne 1&2 remake and CONTROL Resonant , were EUR 6.4 (7.4) million.
EBITDA was EUR -2.4 (4.2) million and operating profit (EBIT) was EUR -3.9 (-0.5)
million.

CONTROL Resonant
CONTROL Resonant’s September 24, 2026 , launch date was revealed in a trailer at a
State of Play presentation in June , followed shortly after by a second trailer at Summer
Game Fest 2026. These trailer reveals lifted our media embargo, and the first hands -on
previews of the game were published.

The early reception has been very strong. CONTROL Resonant drew a lot of praise as
media and content creators went hands -on with a significant portion of the game during
Q2. The move to faster, melee -led action was the most debated aspect following the
announcement , and it has since become one of the most consistently acclaimed
elements of the game, alongside its atmosphere, storytelling and overall feel .
Throughout the second quarter, our development team has continued to raise the
quality of the whole experience , and w e are confident that these elements are coming
together into a spectacular title.

Interest in the game reflects the positive feedback on its quality. As of August 11 th,
2026 , we have over 1.5 million wishlists across platforms . Pre -orders opened with
healthy momentum, and our data indicates the game is tracking well against
comparable titles in its launch window . We are seeing positive traction both in our
traditional and growth marke ts. D uring the campaign window after the pre -order
announce ment , on PlayStation, our analytics show CONTROL Resonant rank ing
among the top three pre -ordered games in the US, Germany and Brazil . It has been
encouraging to see Remedy’s voice resonate broadly with players as we advance in
our self -publishing strategy.

Our first priority is to ship an outstanding game, and that guided how we selected the
release date . We position CONTROL Resonant as a must -have day -one purchase
while also building CONTROL into a lasting franchise . In a competitive autumn window,
we believe the distincti veness and quality of the game will make it stand out.
CONTROL Resonant will be available across all major platforms from day one and is
priced attractively for a n AAA title . Combined with the release window becoming
slightly less crowded since our original reveal, we remain confident in our positioning.

REMEDY ENTERTAINMENT PLC. LUOMANPORTTI 3, 02200 ESPOO, FINLAND 5 (22 )

Games in the market
Control continued its sales momentum in Q2 and delivered growth to the comparison
period . Trailer reveals, release date and live pre -order s for CONTROL Resonant are
renewing interest in the original game which continues to be an important entry point into
the CONTROL franchise for new fans.

Alan Wake 2 ’s consumer sales continued at a n expected pace alongside Alan Wake
Remastered . In the second quarter, royalties from both titles were generated entirely by
consumer sale s and there were no platform deal accruals. Alan Wake 2 ‘s lifetime sales
exceeded 3 million copies during Q2. Rest of the games in the Alan Wake franchise
sold at a normal back -catalogue pace.

Decline in game sales and royalties was mainly caused by FBC: Firebreak ’s launch in
the comparison period. In the second quarter, most of FBC: Firebreak ’s sales were
revenue accruals from subscription service agreements.

Heading to an important second half
In the second half of 2026 , years of work come together in September with the release
of CONTROL Resonant : expanding the CONTROL franchise by developing and self –
publishing the sequel, with our own voice . Our early indicators put the game alongside
the industry’s major releases .

The weeks ahead are about execution. Early signals and commercial metrics give us
confidence in the game’s potential, but our focus remains on bring ing an outstanding
game to the market and letting the results speak. I personally see the game getting
stronger week by week and our marketing accelerates further in the third quarter .

Along the road to our largest and most ambitious release to date , our existing
catalogue has provided a solid backbone and our other development projects
advanced in line with plans , with our new project moving to production readiness . I
want to thank the entire studio for its outstanding work and dedication .
Games in development
Game Publisher Stage -gate status
CONTROL Resonant Remedy Entertainment Full production
New project Remedy Entertainment Production readiness
Max Payne 1&2 remake Rockstar Games Full production

REMEDY ENTERTAINMENT PLC. LUOMANPORTTI 3, 02200 ESPOO, FINLAND 6 (22 )

Outlook 202 6 (unchanged)
Remedy expects its full year revenue and EBITDA to increase from the previous year.
Long -term business prospects
We have two established own franchises, CONTROL and Alan Wake, which are linked
through the Remedy Connected Universe. Remedy will self -publish upcoming games,
in which Remedy owns the IP. Growing and expanding the two franchises will be a key
part of our future. In addition, we work with a partner franchise Max Payne, originally
created by Remedy.

By 2030, we aim to be a highly regarded creative studio with sustainable, significant
commercial success. We have set ourselves the following financial targets:
1) Double the 2024 revenue by 2027 with continued growth beyond this milestone
and
2) EBITDA margin of 30% by 2027 and maintain that minimum level throughout
the strategy period.
Webcast
Remedy will host a webcast in English on its H1 202 6 financial results for investors,
analysts and media on August 11 , 202 6, at 12:00 p.m. (EE ST). Remedy’s financial
results will be presented by CEO Jean -Charles Gaudechon and CFO Santtu
Kallionpää.

The Half -Year Financial Report will be available after publication on Remedy’s Investor
website: https://investors.remedygames.com/financials -and -reports/financial -reports/ .
Webcast details:
Register in advance for the webcast:
https://remedy.videosync.fi/q2 -2026/register

After registering, you will receive a confirmation email containing information about
joining the webcast.

A recording of the webcast will be available afterwards on Remedy’s Investor website:
https://investors.remedygames.com/financials -and -reports/financial -reports/ .
More information
Aapo Kilpinen, Investor Relations & Business Development Manager
Phone: +358 44 522 0595
Email: [email protected]

REMEDY ENTERTAINMENT PLC. LUOMANPORTTI 3, 02200 ESPOO, FINLAND 7 (22 )

Remedy in brief
Remedy Entertainment Plc is a pioneering, globally renowned video game company
founded in 1995 and headquartered in Finland with an office in Stockholm, Sweden.
Known for its story -driven and visually stunning action games, Remedy has created
multiple succ essful, critically acclaimed franchises such as C ONTROL , Alan Wake and
Max Payne. Remedy also develops its own Northlight game engine and tools
technology that powers its games. Remedy’s shares are listed on Nasdaq Helsinki’s
main list.

www.remedygames.com

REMEDY ENTERTAINMENT PLC. LUOMANPORTTI 3, 02200 ESPOO, FINLAND 8 (22 )

Result from business operations

April –June 202 6
In April ‒June 202 6, Remedy’s revenue was EUR 10.2 (16.9) million , decreas ing by
40 .0% from the comparison period . Development fees were EUR 6.4 (7.4) million , and
game sales and royalties were EUR 3.8 (9.5) million. While both development fees as
well as game sales and royalties decreased from the comparison period, t he decrease
in revenue was mainly driven by the initial revenue accruals related to the launch of
FBC: Firebreak in Q2 2025. For the reporting period, t he main sources of revenue were
development fees from Max Payne 1&2 remake and CONTROL Resonant as well as
game sales from Control . Perio d also included game sales from FBC: F irebreak , mainly
consisting of subscri ption service a greement accruals , and royalties from Alan Wake 2.

In April ‒June 202 6, Remedy’s EBITDA was EUR -2.4 (4.2) million and operating profit
(EBIT) was EUR -3.9 (-0.5) million. Materials and services expenses, at EUR 1. 6
million, were EUR 2.0 million lower than in the comparison period , driven by lower
external development expenses in the game projects. Personnel expenses, at EUR 6. 7
million, were 4.8% higher than in the comparison period. While t he ave rage number of
personnel also increased by 0.5% , the main driver s of the increase in personnel
expenses were general increase in salary levels and additional efforts ahead of the
approaching game launch . Depreciation expenses were EUR 1. 6 million, being EUR
3.1 million low er than in the comparison period , as the depreciation related to
capitalized development expenses follow closely the level of the game sales . During
the second quarter, depreciation of capitalized development expenses was related to
Alan Wake 2 and FBC: Firebreak games . Other operating expenses , at EUR 4.4
million, increased by EUR 1.7 million as the marketing for CONTROL Resonant
ramped up in Q 2 2026 .

January –June 2026
In January‒ June 2026, Remedy’s revenue decreased by 23 .1% in relation to the
comparison period, amounting to EUR 23.3 (30.3) million. Development fees were EUR
14 .5 (18.1) million. Game sales and royalties were EUR 8.8 (12.2) million. The main
sources of revenue during H1 2026 were development fees from Max Payne 1&2
remake and CONTROL Resonant . Alan Wake 2 continued to accrue royalties and
Control as well as FBC: Firebrea k accumulated game sales for the reporting period .

In January‒ June 2026, Remedy’s EBITDA was EUR 0.5 (6. 8) million and operating
profit (EBIT) was EUR -2.9 (0.8) million. Materials and services expenses, at EUR 2.8
million, were EUR 3.4 million lower than in the comparison period . Personnel
expenses, at EUR 13 .1 million, were 4.9% higher than in the comparison period.
Depreciation expenses were EUR 3.5 million, being EUR 2.5 million lower than in the
comparison period. Other operating expenses, at EUR 7. 1 million, also increased by
EUR 2.2 million during H1 2026. This was driven by increasing marketing activity
ahead of the game’s launch .

REMEDY ENTERTAINMENT PLC. LUOMANPORTTI 3, 02200 ESPOO, FINLAND 9 (22 )

Cash flow and financial position

Cash flow

April –June 202 6
In April ‒June 202 6, Remedy’s net cash flow was EUR -4.8 (-0.7) million. Cash flow
from business operations was EUR -0.7 (3.1) million. Both t he outgoing payments
related to operating expenses as well as the incoming pay ment s during the reporting
period were at a low er level than in the comparison period , reflecting the reporting
period’s lower revenue and timing of expense payments .

In April ‒June 202 6, Remedy’s cash flow from investing activities amounted to EUR -3.8
(-3.3) million and cash flow from financing activities amounted to EUR -0.4
(-0.6) million. The payments related to inves ting activities were on a higher level as the
amount of capitalized development costs increased from the comparison period.
January –June 2026
In January‒ June 2026, Remedy’s net cash flow was EUR -0.1 (-11.0) million. Cash
flow from business operations amounted to EUR 7.6 ( -3.5) million. In overall , the
incoming payment s were at a higher level during H1 2026 than on the comparison
period. This was due to timing of the incoming payments , as the trade receivables
decreased simultaneously during th is period.

In January‒ June 2026, Remedy’s cash flow from investing activities was EUR -7.0
(-6.7) million and cash flow from financing activities was EUR -0.7 (-0.8) million. In the
comparison period, the cash flow from financi ng activities was impacted by share
subscriptions and the purchase of 2019 stock option rights .
Financial position
Remedy’s non -current assets on June 30, 202 6, were EUR 46.9 (54.7) million in total .
The decrease in non -current assets from the compa rison period is largely due to
depreciation and impa irment expenses related to the capitalized game projects .
Remedy has several projects , wh ich product development costs , as well as the
publishing rights of C ONTROL franchise , are capitalized according to IFRS standards.
The total amount of capitalized product development expenses was EUR 25.1 (29.4)
million on June 30, 202 6. Currently, the m ajority of the capitalized product development
expenses are related to CONTROL Resonant . Other intangible assets amounted to
EUR 7. 5 (12.5) million and comprised of purchased CONTROL related publishing and
distribution rights, of which the majority are also allocated to CONTROL Resonant.

On June 30, 202 6, Remedy’s cash position was EUR 9.6 (10.0) million and other
current financial assets were EUR 20 .0 (17 .5) million. Other current financial assets
include Remedy’s liquid cash management investments.

REMEDY ENTERTAINMENT PLC. LUOMANPORTTI 3, 02200 ESPOO, FINLAND 10 (22 )

The company’s liabilities on June 30, 202 6, amounted to EUR 30 .2 (27 .9) million. The
amount contains EUR 1 5.6 million convertible loan liabilities related to the agreement
Remedy entered with Tencent in September 2024. EUR 1.5 million of the agreement’s
total convertible loan liability is presented as part of the company’s equity as required
by the IFRS standards.

Remedy’s balance sheet total on June 30, 202 6, was EUR 85.1 (97.5) million and
equity EUR 54.9 (69.6) million. The company’s equity ratio was 65.3 % ( 72.8%) and net
gearing -21.4% ( -14.4%).
Personnel, management and governance
The number of the company’s personnel (headcount) was 3 79 (385 ) at the end of the
period under review, decreasing by 1.6% on an annual basis . The average number of
personnel (FTE) was 37 2 (370 ) during the reporting period , with a grow th of 0.5% from
the comparison period . Of the personnel, 5 3% represent 3 8 different nationalities, and
the rest (4 7%) are Finnish.

At the end of the period under review, the company’s Core Management Team
comprised CEO Jean -Charles Gaudechon , CFO Santtu Kallionpää, Chief Product
Officer Markus Mäki, Creative Director Sami Järvi, Creative Director Mikael Kasurinen,
Chief Commercial Officer Johannes Paloheimo and Chief Technology Officer Mika
Vehkala .

Annual General Meeting

Remedy’s Annual General Meeting was held on May 21 , 20 26 , at the company’s office
at Luomanportti 3, 02200 Espoo, Finland.

The Annual General Meeting approved all proposals made to the Annual General
Meeting in the form included in the notice to the Annual General Meeting. Among other
things, the Annual General Meeting resolved to
– adopt the company’s Financial Statements for 202 5,
– to discharge the members of the Board of Directors and the CEO from liability
for the financial year 2025,
– to approve the company’s Remuneration Report ,
– not to distribute a dividend for the financial period ended on December 31,
202 5, and
– to re-elect Markus Mäki, Henri Österlund, Kaisa Salakka, Sonja Ängeslevä and
Kai Tavakka to the Board of Directors and to elect Sean Brennan as a new
Board Member . At its organiz ing meeting held after the Annual General
Meeting, the Board of Directors elected Henri Österlund as the Chairman of the
Board of Directors .

REMEDY ENTERTAINMENT PLC. LUOMANPORTTI 3, 02200 ESPOO, FINLAND 11 (22 )

Further information about the resolutions made by the Annual General Meeting can be
found in Remedy’s Annual General Meeting resolutions release dated May 21 , 202 6,
available on https://investors.remedygames.com/annual -general -meeting -2026/ .
Shares, shareholders and share -based incentive schemes
Remedy’s shares are traded in Nasdaq Helsinki with the trading code REMEDY. The
closing price of Remedy’s shares on the last trading day of the review period was 14.50
euros.

January –June
202 6
Highest share
price, €
Lowest
share price, €
Closing
share price, €
Volume -weighted
average price, €
Remedy 16.18 11.10 14.50 13.68

June 30,
202 6
June 30,
202 5
December 31,
202 5
Market capitalization, € 197 ,061 ,540 202 ,151 ,484 206 ,574 ,855
Number of shareholders 16,778 17, 008 16,365
Number of shares at the end of period 13, 640 ,451 13, 640 ,451 13, 640 ,451
Number of shares outstanding at the end of
period 13,590,451 13, 640 ,451 13,590,451
Average number of shares outstanding within
period 13, 590 ,451 13,5 95,034 13, 610 ,679
Average number of shares outstanding within
period, diluted (IFRS)* 13, 590 ,451 13, 649,244 13, 637 ,784
Average number of shares outstanding within
period, diluted 13,590 ,451 13,735 ,617 13, 680 ,971
Value of share turnover within period 13 ,783 ,741 15 ,152 ,290 27 ,742 ,810
Total number of traded shares within period 1,007 ,599 1,020 ,780 1,883 ,682
*Calculated according to International Financial Reporting Standards (IFRS) .

The company has one series of shares (ISIN: FI4000251897). The number of shares in
the company was 13,640,451 on June 30, 2026, of which Remedy held 50,000
treasury shares. Excluding the treasury shares, the number of outstanding shares at
the end of period was 13,590,451.

On May 21 , 202 6, the Annual General Meeting granted the Board of Directors an
authorisation to resolve on the issuance of new shares, treasury shares and option
rights or other special rights to shares in one or several instalments either against
payment or without payme nt so that the number of shares to be issued can be at
maximum 1,000,000. On June 30, 2026, the authorization had not been used and thus,
a total maximum of 1,000,000 new shares could be issued under the authorization on
said date.

REMEDY ENTERTAINMENT PLC. LUOMANPORTTI 3, 02200 ESPOO, FINLAND 12 (22 )

Major shareholders on June 30, 202 6
Name Shares Percentage
1. Mäki Markus 3,197,000 23. 4
2. Järvi Sami 560,000 4.1
3. Virtala Tero 288,125 2.1
4. Lehtinen Saku 198 ,500 1.5
5. Sijoitusrahasto Aktia Capital 188 ,807 1.4
6. Varma Mutual Pension Insurance Company 150 ,000 1.1
7. Evli Finnish Small Cap Fund 143 ,205 1.0
8. Proprius Partners Micro Finland ( Non -Ucits) 130 ,000 1.0
9. Paloheimo Johannes 106 ,000 0.8
10 . Pulkkinen Janne 10 0,000 0.7
10 largest shareholders total 5,061 ,637 37. 1
Accendo Capital SICAV RAIF (nominee registered) 2,063,162 15. 1
Other nominee registered 2,565 ,368 18.8
Other shares 3,900 ,284 28.6
Treasury shares 50,000 0.4
Total 13, 640 ,451 100.0%

REMEDY ENTERTAINMENT PLC. LUOMANPORTTI 3, 02200 ESPOO, FINLAND 13 (22 )

Option plans
During the reporting period, Remedy has had six option plans directed to Remedy’s
key persons: Option Plan 20 20 , Option Plan 202 1, Option Plan 202 2, Option Plan
202 3, Option Plan 202 4 and Option Plan 2025 . The table below illustrates the key
information about the option plans. More information about the option plans can be
found on Remedy’s website at https://investors.remedygames.com/remuneration/ .
Key information about the option plans as of June 30, 202 6
Option
Plan
Maximum
number of
option rights
issued
Number of
allocated
option
rights
Number of
unexercised
option rights
Share subscription period Share
subscription
price, EUR
Option
Plan
2020
179,500 179,500 0 June 1, 2023 – May 31, 2026 22.21
Option
Plan
2021
270,000 270,000 270,000 June 1, 2024 – May 31, 2027 47.09
Option
Plan
2022
292,000 292,000 292,000 June 1, 2025 – May 31, 2028 26.64
Option
Plan
2023
350 ,000 306 ,000 306 ,000 June 1, 2026 – May 31, 2029 27.31
Option
Plan
2024
350,000 324,000 324,000 June 1, 2027 – May 31, 2030 19.76
Option
Plan
2025
350,000 331,000 331,000 June 1, 2028 – May 31, 2031 16.66

Option Plan 20 20 ended on May 31, 202 6.

Option Plan 2023 vested on June 1, 2026. Originally, a total number of 350,000 option
rights 2023 were issued , of which Remedy will cancel a total of 44 ,000 option rights
held by the company. The remaining 306 ,000 option rights entitle their holders to
subscribe for a corresponding amount of company shares.

REMEDY ENTERTAINMENT PLC. LUOMANPORTTI 3, 02200 ESPOO, FINLAND 14 (22 )

Risks and uncertainties
The most substantial short -term risks and uncertainties are:

• Remedy’s game development efforts may fail if the company is unable to develop
its games within set mandates, such as release schedule, quality, and budget.
Additionally, the company’s games may not generate sufficient sales after their
release, even if we ll received and of high quality, thus generating less than
estimated game revenue for Remedy.
• Remedy has entered into long -term agreements with its partners related to game
projects in development and game sales. If the company failed to satisfy key
contract obligations, its partners could terminate their agreements with, or present
claims to, the company.
• Remedy is self -publishing its games based on fully owned IPs and is in this way
taking more financing risk in game development. In case the self -published games
are not successful and do not generate sufficient sales, Remedy carries the risk of
the games n ot becoming profitable.
• Remedy’s success depends significantly on its ability to hire, train, and retain skilled
personnel. If the company fails in these areas, it will be unable to effectively
conduct its business.
• Remedy’s business is subject to economic, market, and geopolitical conditions,
which are beyond its control. Possible significant fluctuations in currencies,
especially USD exchange rate, could have effects on Remedy’s profitability.

The above -mentioned risks might, if they materialize, have a significant negative
impact on Remedy’s business operations, result, financial position, outlook and share
price.

Events after the end of the reporting period
Remedy received the following flagging notifications after the reporting period.
Mariatorp Oy’s total holding increased above the 5% threshold on July 7, 202 6. Markus
Mäki’s total holding decreased below the 20 % threshold on July 7, 2026. Accendo
Capital SICAV RAIF’s total holding decreased below the 15 % threshold on July 7 ,
202 6.

There haven’t been any other significant events after the end of the review period.

REMEDY ENTERTAINMENT PLC. LUOMANPORTTI 3, 02200 ESPOO, FINLAND 15 (22 )

Tables

Consolidated statement of comprehensive income
EUR thousand 4–6/2026 4–6/2025 1–6/2026 1–6/202 5 1–12/2025
REVENUE 10,157 16,915 23,299 30,313 59,510
Development fees 6,353 7,396 14 ,542 18,146 32,947
Game sales and royalties 3,804 9,519 8,756 12 ,167 26,562
Other operating income 151 0 21 5 0 0
Materials and services -1,604 -3,636 -2,832 -6,220 -12,240
Game development related
materials and services -1,151 -3,162 -2,058 -5,616 -10,471
Revenue related partner expenses -452 -474 -77 3 -605 -1,769
Personnel expenses -6,736 -6,429 -13 ,077 -12 ,465 -24,896
Depreciation, amortization and
impairment -1,551 -4,667 -3,452 -5,955 -26,206
Other operating expenses -4,362 -2,643 -7,07 0 -4,838 -11,031
OPERATING PROFIT (LOSS) -3,946 -459 -2,916 835 -14,863
Financial income 488 458 50 1 724 1,150
Financial expenses -455 -559 -745 -1,020 -1,991
PROFIT (LOSS) BEFORE INCOME
TAXES -3,91 2 -560 -3,160 539 -15,703
Income taxes 668 -7 393 -516 2,673
PROFIT (LOSS) FOR THE FINANCIAL
YEAR -3,24 4 -568 -2,76 8 23 -13,030
OTHER COMPREHENSIVE INCOME
(EXPENSE)
Items that may be subsequently
reclassified to profit or loss 0 0 0 0 0
Total other comprehensive income
(expense) for the financial year 0 0 0 0 0
TOTAL COMPREHENSIVE INCOME
(EXPENSE) FOR THE FINANCIAL
YEAR -3,24 4 -568 -2,76 8 23 -13,030
PROFIT (LOSS) FOR THE FINANCIAL
YEAR ATTRIBUTABLE TO OWNERS
OF THE COMPANY -3,24 4 -568 -2,76 8 23 -13,030

EARNINGS PER SHARE
Basic earnings per share, euro -0.24 -0.04 -0.20 0.0 0 -0.96
Diluted earnings per share, euro -0.24 -0.04 -0.20 0.0 0 -0.96

REMEDY ENTERTAINMENT PLC. LUOMANPORTTI 3, 02200 ESPOO, FINLAND 16 (22 )

Consolidated statement of financial position
EUR thousand June 30, 202 6 June 30, 202 5 December 31, 202 5
ASSETS

NON -CURRENT ASSETS
Intangible assets 32,541 41,916 27 ,933
Tangible assets 2,020 2,919 2,369
Right -of-use assets 2,780 4,061 3,391
Non -current receivables 751 744 751
Deferred tax assets 8,759 5,071 8,308
TOTAL NON -CURRENT ASSETS 46,852 54,711 42 ,752

CURRENT ASSETS
Trade and other receivables 8,635 15,211 15 ,402
Derivative financial instruments 0 21 0
Current financial assets 20 ,034 17,527 19 ,754
Cash and cash equivalents 9,562 10 ,029 9,641
TOTAL CURRENT ASSETS 38 ,231 42,789 44,797

TOTAL ASSETS 85,082 97,500 87 ,548

REMEDY ENTERTAINMENT PLC. LUOMANPORTTI 3, 02200 ESPOO, FINLAND 17 (22 )

EUR thousand June 30, 202 6 June 30, 202 5 December 31, 202 5
EQUITY AND LIABILITIES

EQUITY
Share capital 80 80 80
Share premium 38 38 38
Invested non -restricted equity
reserve 58, 169 58, 855 58, 169
Retained earnings (losses) -614 10,578 11,337
Profit (loss) for the financial year -2,76 8 23 -13,030
TOTAL EQUITY 54,905 69,573 56 ,594

LIABILITIES

NON -CURRENT LIABILITIES
Convertible bonds 15,003 13,4 73 14,838
Lease liabilities 1,496 2,790 2,12 3
Accrued expenses 648 600 0
Deferred tax liabilities 199 181 196
TOTAL NON -CURRENT
LIABILITIES 17,346 17,044 17,157

CURRENT LIABILITIES
Lease liabilities 1,338 1,288 1,3 06
Trade and other payables 11 ,494 9,595 12,491
TOTAL CURRENT LIABILITIES 12,831 10,883 13,797

TOTAL LIABILITIES 30 ,177 27 ,927 30, 954

TOTAL EQUITY AND LIABILITIES 85,082 97 ,500 87 ,548

REMEDY ENTERTAINMENT PLC. LUOMANPORTTI 3, 02200 ESPOO, FINLAND 18 (22 )

Condensed consolidated statement of cash flow

EUR thousand 1–6/202 6 1–6/202 5 1–12/202 5
Cash flow from operati ng activities 7,617 -3,482 4,513
Cash flow from invest ing activities * -6,978 -6,661 -13 ,646
Cash flow from financing activities -718 -824 -2,222

Liquid assets – opening balance 9,641 20, 996 20, 996
Change in liquid assets -79 -10,967 -11, 356
Liquid assets – closing balance 9,562 10,029 9,641
*Includes capitalized development costs in January -June 202 6 EUR -6,716 (in January -June 202 5 EUR
-6,105 ) thousand .

REMEDY ENTERTAINMENT PLC. LUOMANPORTTI 3, 02200 ESPOO, FINLAND 19 (22 )

Consolidated statement of changes in equity
Changes in shareholders’
equity 1 –6/202 6
Share
capital
Share
premium
Invested no n-
restricted
equity reserve
Retained
earnings
SHARE –
HOLDERS’
EQUITY TOTAL
EUR thousand
Balance January 1, 202 6 80 38 58,169 -1,693 56 ,594
Comprehensive income
Profit (Loss) for the financial
year -2,76 8 -2,76 8
Other comprehensive income
Total comprehensive
income -2,76 8 -2,76 8
Transactions with owners
of the company
Share options granted 1,079 1,079
Total transactions with
owners 1,079 1,079
BALANCE
June 30, 202 6 80 38 58,169 -3,382 54,905

Changes in shareholders’
equity 1 –6/202 5
Share
capital
Share
premium
Invested no n-
restricted
equity reserve
Retained
earnings
SHARE –
HOLDERS’
EQUITY TOTAL
EUR thousand
Balance January 1, 202 5 80 38 58,344 10 ,065 68,527
Comprehensive income
Profit (Loss) for the financial
year 23 23
Other comprehensive income
Total comprehensive
income 23 23
Transactions with owners
of the company
Share options granted 1,223 1,223
Share issue and other share
subscriptions 510 510
Purchase of option right s -710 -710
Total transactions with
owners 510 513 1,023
BALANCE
June 30, 202 5 80 38 58, 855 10,601 69,573

REMEDY ENTERTAINMENT PLC. LUOMANPORTTI 3, 02200 ESPOO, FINLAND 20 (22 )

Notes to the Half -Year Financial Re port January –June 202 6

Accounting policies applied in the Half -Year Financial Report

The Half -Year Financial Report has been prepared in accordance with IAS 34 ‘Interim
Financial Reporting’ while adhering to related IFRS standards applicable within the EU
on June 30, 202 6. The accounting policies of the Half -Year Financial Report are similar
to the accounting policies applied in the Financial Statements according to IFRS for the
period ended December 31, 202 5. The disclosed figures have been rounded off from
the accurate figures.

The information presented in this Half -Year Financial R eport is unaudited.
Revenue breakdown per quarter
EUR thousand 4–6/2026 1–3/2026 10 –12/2025 7–9/2025 4–6/2025
Development fees 6,353 8,189 8,687 6,115 7,396
Game sales and
royalties 3,804 4,952 8,354 6,041 9,519
Total 10,157 13,141 17,041 12,156 16,915

Fair value measurement and hierarchy of financial instruments

Currently Remedy’s financial assets and liabilities measured at fair value comprise of
derivative assets and derivative liabilities and investments to equity funds.

June 30, 202 6 Carrying
amount Fair value

EUR thousand Level 1 Level 2 Level 3 Total

Financial assets measured at fair value
Investments to equity funds 20,034 20,034 – – 20,034
20 ,034 20 ,034 – – 20 ,034
Financial liabilities not measured at fair value
Convertible bonds 15,003 – – 15,003 15,003
15,003 – – 15,003 15,003

REMEDY ENTERTAINMENT PLC. LUOMANPORTTI 3, 02200 ESPOO, FINLAND 21 (22 )

December 31, 202 5 Carrying
amount Fair value

EUR thousand Level 1 Level 2 Level 3 Total
Financial assets measured at fair value
Investments to equity funds 19 ,754 19 ,754 – – 19 ,754
19 ,754 19 ,754 – – 19 ,754
Financial liabilities not measured at fair value
Convertible bonds 14,838 – – 14,838 14,838
14,838 – – 14,838 14,838

Level 1: fair value is calculated on the basis of quoted prices (unadjusted) in active
markets for identical assets or liabilities that Remedy can access at the
measurement date.
Level 2: fair value is calculated on the basis of inputs other than quoted prices included
in Level 1 that are observable for the asset or liability; either directly (i.e. as prices)
or indirectly (i.e. derived from prices).
Level 3: fair value is calculated on the basis of inputs for the asset or liability that are
not based on observable market data (unobservable inputs).

When measuring the fair value of an asset or a liability, Remedy uses observable
market data as far as possible.
Changes in tangible assets
EUR thousand
Machinery and
equipment
Other tangible
assets Total
202 6 202 5 202 6 202 5 202 6 202 5
Cost
Balance January 1 10 ,059 9,550 1,9 88 1,988 12,048 11,538
Additions 328 318 0 0 328 318
Balance June 30 10 ,387 9,868 1,9 88 1,988 12,375 11, 856

Accumulated depreciation and
impairment
Balance January 1 -7,708 -6,233 -1,971 -1,9 47 -9,679 -8,180
Depreciation -662 -745 -15 -12 -676 -757
Balance June 30 -8,370 -6,97 8 -1,9 85 -1,9 59 -10 ,355 -8,937

Carrying amount on January 1 2,351 3,316 17 41 2,369 3,357
Carrying amount on June 30 2,017 2,890 3 29 2,020 2,919

REMEDY ENTERTAINMENT PLC. LUOMANPORTTI 3, 02200 ESPOO, FINLAND 22 (22 )

Changes in intangible assets
EUR thousand
Capitalized
development
costs Other intangible
assets Total
202 6 202 5 202 6 202 5 202 6 202 5
Cost
Balance January 1 56,988 46 ,026 16, 945 16,416 73 ,932 62 ,441
Additions 6,716 6,105 0 529 6,716 6,635
Balance June 30 63,704 52 ,131 16,945 16, 945 80 ,648 69,076

Accumulated amortization and
impairment
Balance January 1 -36 ,819 -19,197 -9,181 -3,430 -45 ,999 -22 ,626
Amortization -1,8 24 -3,491 -284 -1,042 -2,108 -4,533
Balance June 30 -38,643 -22 ,688 -9,464 -4,472 -48,107 -27,160

Carrying amount on January 1 20,169 26 ,829 7,764 12,986 27 ,933 39 ,815
Carrying amount on June 30 25,061 29,443 7,480 12,473 32,541 41,916

Calculation formulas used for the indicators
EBITDA: Operating profit (EBIT) + Depreciation, amortization and impairment
Operating profit (EBIT): Profit (loss) before taxes and financial items
Operating profit, % of revenue: Operating profit (EBIT) / revenue
Net cash: Cash in hand and banks + liquid investments* – interest -bearing liabilities
Net gearing, %: (Interest -bearing liabilities – cash in hand and at banks – liquid
investments*) / shareholders’ equity
Equity ratio , % : Shareholders’ equity / (balance sheet total – advances received)
Capital Expenditures: Change in tangible and intangible assets added by
depreciation of these assets

*Liquid investments include Remedy’s liquid investments to equity funds. All of these investments are in
cash, money market, or fixed income instruments.

Espoo, August 11 , 202 6
Remedy Entertainment Plc
Board of Directors